Case Report

Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in Treatment of a Patient with Chronic Hepatitis B

Authors: Kendal Yalcin, MD, Halil Degertekin, MD, Mithat Bozdayi, MD, PHD

Abstract

We report the first case of a woman having chronic hepatitis B treated with a combination therapy of recombinant hepatitis B vaccine and lamivudine for 18 months. The main aims of such a combined therapy were to assess whether the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the emergence of a mutant HBV and lead to sustained hepatitis B e antigen seroconversion with undetectable serum HBV DNA. The data from the present case demonstrated that combination of anti-HBV vaccine and lamivudine did not eliminate viral DNA despite prolonged treatment and did not have any effect on preventing resistant-type HBV. Although the combined therapy failed to reach the therapeutic endpoints, it concerned a single and unique patient. Hepatitis B vaccine and lamivudine for HBV treatment should be further investigated in randomized controlled trials.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–180.
 
2. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714–717.
 
3. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995; 49: 105–109.
 
4. Michel ML, Pol S, Brechot C, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19: 2395–2399.
 
5. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968–975.
 
6. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963–971.
 
7. Hervas-Stubbs S, Lasarte JJ, Sarobe P, et al. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 2001; 35: 105–111.
 
8. Dahmen A, Herzog-Hauff S, Bocher WO, et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002; 66: 452–460.
 
9. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917–921.
 
10. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58: 101–141.
 
11. Heintges T, Petry W, Kaldewey M, et al. Combination therapy of active HBsAg vaccination and interferon-α in interferon-α nonresponders with chronic hepatitis B. Dig Dis Sci 2001; 46: 901–906.